Comparative Pharmacology
Head-to-head clinical analysis: BRIXADI versus BUPRENORPHINE HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BRIXADI versus BUPRENORPHINE HYDROCHLORIDE.
BRIXADI vs BUPRENORPHINE HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Buprenorphine is a partial agonist at mu-opioid receptors and an antagonist at kappa-opioid receptors, reducing opioid withdrawal symptoms and cravings.
Partial agonist at mu-opioid receptors and antagonist at kappa-opioid receptors, producing analgesia and reducing opioid withdrawal symptoms.
Brixadi (buprenorphine) extended-release injection for subcutaneous use: Patients on transmucosal buprenorphine products, after a single dose of 8-24 mg transmucosal buprenorphine, administer Brixadi as a subcutaneous injection once weekly: 8 mg/week for patients on 8-16 mg/day transmucosal buprenorphine, 16 mg/week for patients on 12-24 mg/day, 24 mg/week for patients on 16-24 mg/day. Alternatively, monthly injection: 64 mg/month for patients on 8-16 mg/day, 96 mg/month for patients on 12-24 mg/day, 128 mg/month for patients on 16-24 mg/day.
Sublingual: 8-16 mg once daily. Transdermal: 5-20 mcg/hour applied every 7 days. Injectable: 0.3 mg IM/IV every 6-8 hours as needed.
None Documented
None Documented
Terminal half-life approximately 470–500 hours (~20 days) following intramuscular injection, allowing weekly or monthly dosing.
Terminal elimination half-life is 20-73 hours (mean ~37 hours); prolonged half-life supports sublingual dosing every 24-48 hours in opioid dependence.
Primarily fecal (80–90%) as unchanged drug; renal elimination accounts for <5% of the dose.
Primarily fecal (70%) via biliary excretion; renal excretion accounts for 20-30% as unchanged drug and metabolites (mainly norbuprenorphine glucuronide).
Category C
Category C
Opioid Partial Agonist
Opioid Partial Agonist